Amgen still hopes new cardiovascular data will solve a problem facing cholesterol drug, Repatha – in almost eight out of ten cases US insurers and Medicare initially refuse to prescribe the drug. One ...
SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...
What Changed in the Amgen Story Amgen’s fair value estimate has been adjusted slightly, moving from about US$322.88 per share ...
The official prescribing information for rosuvastatin (Crestor) includes the following: “... rare postmarketing reports of ...
TrumpRx is supposed to launch in early 2026. Here's what we know about how buying medicine through the site to get discounts ...
Amgen has announced a deal with the US government that will lower the company’s prescription drug costs for US patients while ...
Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of cardiovascular ...
The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for ...
Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...
Barchart on MSN
What to expect from Amgen's Q4 2025 earnings report
The drug manufacturing giant is expected to announce its fiscal fourth-quarter earnings for 2025 in the near term. Ahead of ...
MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...
When it comes to cost, the Wegovy pill is expected to be a $25 or less copay per month if covered by insurance. Without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback